XML 74 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenues	[1]	$ 31,655	$ 26,682	$ 83,479	$ 76,689
Consumables [Member] | Transferred at Point in Time [Member]
Revenues		12,912	12,706	37,241	37,240
Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		12,109	8,556	28,656	23,582
Service [Member] | Transferred at Point in Time [Member]
Revenues		4,217	3,131	10,815	9,133
Service [Member] | Transferred over Time [Member]
Revenues		2,417	2,289	6,767	6,734
Sterilzation and Disinfection Control [Member]
Revenues	[1]	11,619	11,545	35,823	34,475
Sterilzation and Disinfection Control [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues		9,948	9,853	30,487	29,478
Sterilzation and Disinfection Control [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		95	110	429	487
Sterilzation and Disinfection Control [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues		360	372	1,301	884
Sterilzation and Disinfection Control [Member] | Service [Member] | Transferred over Time [Member]
Revenues		1,216	1,210	3,606	3,626
Instruments [Member]
Revenues	[1]	10,014	9,341	28,518	26,776
Instruments [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues		781	834	2,364	2,272
Instruments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		6,881	6,417	19,282	18,039
Instruments [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues		2,352	2,090	6,872	6,465
Instruments [Member] | Service [Member] | Transferred over Time [Member]
Revenues
Biopharmaceutical Development [Member]
Revenues	[1]	5,637		5,637
Biopharmaceutical Development [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues		1,941		1,941
Biopharmaceutical Development [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		2,571		2,571
Biopharmaceutical Development [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues		656		656
Biopharmaceutical Development [Member] | Service [Member] | Transferred over Time [Member]
Revenues		469		469
Cold Chain Monitoring [Member]
Revenues	[1]	4,156	3,744	11,059	9,917
Cold Chain Monitoring [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues		13	151	34	351
Cold Chain Monitoring [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		2,562	1,980	6,374	4,951
Cold Chain Monitoring [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues		849	534	1,959	1,507
Cold Chain Monitoring [Member] | Service [Member] | Transferred over Time [Member]
Revenues		732	1,079	2,692	3,108
Cold Chain Packaging [Member]
Revenues	[1]	229	2,052	2,442	5,521
Cold Chain Packaging [Member] | Consumables [Member] | Transferred at Point in Time [Member]
Revenues		229	1,868	2,415	5,139
Cold Chain Packaging [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues			49		105
Cold Chain Packaging [Member] | Service [Member] | Transferred at Point in Time [Member]
Revenues			135	27	277
Cold Chain Packaging [Member] | Service [Member] | Transferred over Time [Member]
Revenues
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=mlab_ConsumablesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mlab_HardwareAndSoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_SterilzationAndDisinfectionControlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_InstrumentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_ColdChainMonitoringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_ColdChainPackagingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: